Nora D. Volkow

Nora D. Volkow

Auto-generated profile, based on publicly available information

Nora D. Volkow

Brookhaven National Laboratory, Upton, NY 11973, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
NVNora D. Volkow
Nora D. Volkow
JFJoanna S. Fowler
Joanna S. Fowler
Understanding the changes in the brain which occur in the transition from normal to addictive behavior has major implications in public health. Here we postulate that while reward circuits (nucleus accumbens, amygdala), which have been central to theories of drug addiction, may be crucial to initiate drug self-administration, the addictive state also involves disruption of circuits involved with compulsive behaviors and with drive. We postulate that intermittent dopaminergic activation of reward circuits secondary to drug self-administration leads to dysfunction of the orbitofrontal cortex via the striato-thalamo-orbitofrontal circuit. This is supported by imaging studies showing that in drug abusers studied during protracted withdrawal, the orbitofrontal cortex is hypoactive in proportion to the levels of dopamine D2 receptors in the striatum. In contrast, when drug abusers are tested shortly after last cocaine use or during drug-induced craving, the orbitofrontal cortex is hypermetabolic in proportion to the intensity of the craving. Because the orbitofrontal cortex is involved with drive and with compulsive repetitive behaviors, its abnormal activation in the addicted subject could explain why compulsive drug self-administration occurs even with tolerance to the pleasurable drug effects and in the presence of adverse reactions. This model implies that pleasure per se is not enough to maintain compulsive drug administration in the drugaddicted subject and that drugs that could interfere with the activation of the striato-thalamo-orbitofrontal circuit could be beneficial in the treatment of drug addiction.

1 March 2001 in American Journal of Psychiatry
Verified
Journal Article
Closed access
NVNora D. Volkow
Nora D. Volkow
LCLinda Chang
Linda Chang
GWGene-Jack Wang
Gene-Jack Wang
JFJoanna S. Fowler
Joanna S. Fowler
MLMaria Leonido-Yee
Maria Leonido-Yee
EMEric N. Miller
Eric N. Miller

1 April 1997 in Nature
Verified
Journal Article
Open access
PDF file
NVN. D. Volkow
N. D. Volkow
GWG.-J. Wang
G.-J. Wang
JFJ. S. Fowler
J. S. Fowler
JLJ. Logan
J. Logan
SGS. J. Gatley
S. J. Gatley
NPN. Pappas
N. Pappas
Cocaine blocks the reuptake of dopamine, a neurotransmitter involved in the control of movement, cognition, motivation and reward. This leads to an increase in extracellular dopamine; the reinforcing effect of cocaine is associated with elevated dopamine levels in the nucleus accumbens1,2. But addiction to cocaine involves other effects, such as craving, loss of control and compulsive drug intake; the role of the dopamine system in these effects is less well-understood. We therefore used positron emission tomography (PET) to compare the responses of cocaine addicts and normal controls to intravenous methylphenidate, a drug that, like cocaine, causes an increase in synaptic dopamine3. Addicts showed reduced dopamine release in the striatum, the brain region where the nucleus accumbens is located, and also had a reduced 'high' relative to controls. In contrast, addicts showed an increased response to methylphenidate in the thalamus (a region that conveys sensory input to the cortex). This thalamic response was associated with cocaine craving and was not seen in control subjects. Thus, our findings challenge the notion that addiction involves an enhanced striatal dopamine response to cocaine and/or an enhanced induction of euphoria. Moreover, they suggest a participation of thalamic dopamine pathways in cocaine addiction, a possibility that merits further investigation.

1 December 2001 in American Journal of Psychiatry
Verified
Journal Article
Closed access
NVNora D. Volkow
Nora D. Volkow
LCLinda Chang
Linda Chang
GWGene-Jack Wang
Gene-Jack Wang
JFJoanna S. Fowler
Joanna S. Fowler
YDYu-Sin Ding
Yu-Sin Ding
NPNaomi Pappas
Naomi Pappas

1 October 1998 in American Journal of Psychiatry
Verified
Journal Article
Closed access
NVNora D. Volkow
Nora D. Volkow
GWGene.-Jack Wang
Gene.-Jack Wang
JFJoanna S. Fowler
Joanna S. Fowler
SGSamuel J. Gatley
Samuel J. Gatley
JLJean Logan
Jean Logan
NPNaomi Pappas
Naomi Pappas

15 January 2001 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NVNora D. Volkow
Nora D. Volkow
GWGene-Jack Wang
Gene-Jack Wang
JFJoanna S. Fowler
Joanna S. Fowler
JLJean Logan
Jean Logan
MGMadina Gerasimov
Madina Gerasimov
DFDinko Franceschi
Dinko Franceschi
Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly understood. Whereas methylphenidate blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it is unclear whether at doses used therapeutically it significantly changes extracellular dopamine (DA) concentration. Here we used positron emission tomography and [(11)C]raclopride (D2 receptor radioligand that competes with endogenous DA for binding to the receptor) to evaluate whether oral methylphenidate changes extracellular DA in the human brain in 11 healthy controls. We showed that oral methylphenidate (average dose 0.8 +/- 0.11 mg/kg) significantly increased extracellular DA in brain, as evidenced by a significant reduction in B(max)/K(d) (measure of D2 receptor availability) in striatum (20 +/- 12%; p < 0.0005). These results provide direct evidence that oral methylphenidate at doses within the therapeutic range significantly increases extracellular DA in human brain. This result coupled with recent findings of increased dopamine transporters in ADHD patients (which is expected to result in reductions in extracellular DA) provides a mechanistic framework for the therapeutic efficacy of methylphenidate. The increase in DA caused by the blockade of dopamine transporters by methylphenidate predominantly reflects an amplification of spontaneously released DA, which in turn is responsive to environmental stimulation. Because DA decreases background firing rates and increases signal-to-noise in target neurons, we postulate that the amplification of weak DA signals in subjects with ADHD by methylphenidate would enhance task-specific signaling, improving attention and decreasing distractibility. Alternatively methylphenidate-induced increases in DA, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the "interest that it elicits" and thus improving performance.